You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,358,306


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,358,306
Title:Photosensitizing antibody-fluorophore conjugates
Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm.sup.-2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
Inventor(s): Kobayashi; Hisataka (Laurel, MD), Choyke; Peter (Rockville, MD), Bernardo; Marcelino (Germantown, MD)
Assignee: The United States of America, as rep. by the Secretary, Dept. of Health and Human Services (Washington, DC)
Application Number:14/126,060
Patent Claims:1. A method of treating a tumor in a subject, comprising: administering to the subject a therapeutically effective amount of one or more antibody-IR700 molecules, wherein the antibody specifically binds to a cell surface protein on a tumor cell; administering one or more therapeutic agents to the subject; and irradiating the tumor at a wavelength of 660 to 740 nm and at a dose of at least 1 J cm.sup.-2; thereby treating the tumor in the subject.

2. The method of claim 1, wherein the tumor is a cancer.

3. The method of claim 2, wherein the cancer is a cancer of the breast, liver, colon, ovary, prostate, pancreas, brain, cervix, bone, skin, or lung.

4. The method of claim 1, wherein the tumor cell is a circulating tumor cell.

5. The method of claim 1, wherein the cell surface protein is a tumor-specific protein.

6. The method of claim 1, wherein the cell surface protein is human epidermal growth factor receptor (HER)1, HER2, HER3, HER4, CD5, CD25, CD52, IL-13R, Lewis Y antigen, melanoma-associated antigen (MAGE)1, MAGE2, MAGE3, MAGE4, cancer antigen 125 (CA-125), tumor-associated glycoprotein 72 (TAG-72), gp100, p97 melanoma antigen, human milk fat globule (HMFG), melanoma antigen recognized by T cells 1 (MART1), B melanoma antigen (BAGE) 1, BAGE2, G antigen (GAGE) 1, GAGE2, GAGE3, GAGE4, GAGE5, GAGE6, breast cancer-associated DF3 antigen, New York esophageal squamous cell carcinoma 1 (NY-ESO-1), mesothelin, or carcinoembryonic antigen (CEA).

7. The method of claim 1, wherein the antibody is cetuximab, panitumumab, zalutumumab, nimotuzumab, matuzumab, trastuzumab, pertuzumab, rituximab, daclizumab, J591 or is an antigen binding fragment thereof.

8. The method of claim 1, wherein the tumor is irradiated at a wavelength of 680 nm.

9. The method of claim 1, wherein the one or more antibody-IR700 molecules comprises at least two different antibody-IR700 molecules, wherein a first antibody-IR700 molecule is specific for a first antigen, and a second antibody-IR700 molecule is specific for a different epitope of the first antigen or is specific for a second antigen.

10. The method of claim 1, wherein the tumor cell is a circulating tumor cell, and wherein irradiating the tumor comprises irradiating the blood by using a device worn by the subject, wherein the device comprises a near infrared (NIR) light emitting diode (LED).

11. The method of claim 1, wherein the method further comprises: selecting a subject with a tumor that expresses a cell surface protein that can specifically bind to the one or more antibody-IR700 molecules.

12. The method of claim 1, wherein the method reduces the volume or size of the tumor by at least 25% relative to the absence of administration of the one or more antibody-IR700 molecules and irradiation.

13. The method of claim 1, wherein the method increases survival time of the subject relative to an absence of administration of the one or more antibody-IR700 molecules and irradiation.

14. The method of claim 1, further comprising: contacting the tumor with one or more antibody-IR700 molecules in an amount less than the therapeutically effective amount; and irradiating the tumor at a wavelength of 660 to 740 nm and at a dose of at least 0.001 J cm.sup.-2, thereby permitting detection of the tumor.

15. The method of claim 1, wherein the one or more therapeutic agents is administered about 0 to 8 hours after irradiating the tumor.

16. The method of claim 1, wherein the one or more therapeutic agents is administered prior to, during, or following administration of the one or more antibody-IR700 molecules.

17. The method of claim 1, wherein the one or more therapeutic agents is an anti-cancer or anti-neoplastic agent.

18. The method of claim 1, wherein the one or more therapeutic agents is selected from among a radiotherapeutic agent, a chemotherapeutic agent, an antibiotic, an alkylating agent, an antioxidant and a kinase inhibitor.

19. The method of claim 1, wherein the one or more therapeutic agents is selected from among a microtubule binding agent, a DNA intercalator or cross-linker, a DNA synthesis inhibitor, a DNA or RNA transcription inhibitor, an antibody, an enzyme, an enzyme inhibitor and a compound that affects gene regulation.

20. The method of claim 1, wherein the one or more therapeutic agents is selected from among paclitaxel, docetaxel, vinblastine, vindesine, vinorelbine, epothilone, colchicine, dolastatin 15, nocodazole, podophyllotoxin, rhizoxin, actinomycin D, daunorubicin, cisplatin, carboplatin, oxaliplatin, mitomycin C, bleomycin, chlorambucil, cyclophosphamide, methotrexate, 5-fluro-5'-deoxyuridine, 5-fluorouracil, camptothecin, etoposide, formestane, trichostatin, raloxifene, 5-azacytidine, 5-aza-2'-deoxycytidine, tamoxifen, 4-hydroxytamoxifen, mifepristone, imatinib, gefitnib, erlotinib, adriamycine, apigenin, rapamycine, zebularine, cimetidine, interleukin-2 (IL-2), and an anti-CTLA4 antibody.

21. The method of claim 1, wherein the one or more antibody-IR700 molecules comprises a cetuximab-IR700 molecule.

22. The method of claim 1, wherein the tumor is a carcinoma.

23. The method of claim 22, wherein the tumor is a squamous cell carcinoma or adenocarcinoma.

24. The method of claim 22, wherein the tumor is a carcinoma of the bladder, pancreas, colon, ovary, lung, breast, stomach, prostate, cervix, esophagus or head and neck.

25. The method of claim 1, wherein the antibody is an antigen-binding antibody fragment selected from a Fab fragment, Fab' fragment, F(ab)'2 fragment, single chain Fv (scFv) or a disulfide stabilized Fv (dsFv).

Details for Patent 9,358,306

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2030-07-09
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 02/19/2002 ⤷  Try a Trial 2030-07-09
Hoffmann-la Roche Inc. ZENAPAX daclizumab Injection 103749 12/10/1997 ⤷  Try a Trial 2030-07-09
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2030-07-09
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2030-07-09
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.